Anti-Human CD151 Recombinant Antibody (Humanized 214B2) (CAT#: TAB-1608CL)

Figure 1 shows the analysis, by flow cytometry, of the recognition of CD151 by the murine antibody 214B2 on the surface of NIH 3T3-CD151 cells.

Figure 2 shows the results of evaluation of the specificity of antibodies 20386, 205H8, 211F3 and 21482 by Western blot.

Figure 3 illustrates the anti-tumour activity of anti-CD151 monoclonal antibodies in the PC3 prostate tumour xenograft model.

The PC3 cells were grafted into Swiss Nude mice (n=6) by the subcutaneous route. Five days after grafting of the cells, the mice receive, by the i.p. route, a challenge dose of 2 mg/mouse of the antibody under test followed by two administrations per week of a dose of 1 mg/mouse of that antibody. The tumour volume is determined by the formula π/6×length×width×thickness.

Figure 4 shows the effect of the anti-CD151 antibodies on platelet functions with Platelet aggregation.

Figure 5 shows the effect of anti-CD151 antibodies on the tumour growth, in vivo, of NCI-H441 cells.

Figure 6 illustrates the in vivo activity of the c214B2[IgG1] Mab on tumor growth of PC3, an androgen-independent prostate cell line.